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sive). Non parametric ANOVA analysis was performed to
compare the difference of UCLA-PCI scores by Gleason groups.
RESULTS: A total of 1452 patients were included (mean age:
74.4; SD 8.7). The mean of missing items per patient (0.36)
showed acceptable feasibility. Ceiling effects (£67%) was present
in all dimensions, as well as ﬂoor effects (£48%) in 5 of the 6
dimensions. Cronbach alpha values by dimensions were as
follows: 0.85 for Urinary Function (UF); 0.60 for Bowel Func-
tion (BF); and 0.94 for Sexual Function (SF). For the function
and bother (F-B) related items, internal consistency was: a = 0.51
for Urinary F-B; a = 0.71 for Bowel F-B; and a = 0.89 for Sexual
F-B. There were statistically signiﬁcant between-group differ-
ences in scores on the UCLA-PCI, with patients in Gleason group
A reporting higher scores (better QoL) than Gleason group C.
Likewise, mean differences (MD) in UF dimension scores were
statistically signiﬁcant when comparing Group A to C (MD 
= 6.3, p < 0.001), and Group B to C (MD = 6.4, p < 0.001). In
the BF dimension, MD was signiﬁcant when comparing Group
A to C (MD = 3.9 p = 0.001), and Group B to C (MD = 4.4, 
p = 0.001); and in the SF dimension when comparing Group A
to B (MD = 4.5, p = 0.015), and Group A to C (MD = 7.5, 
p < 0.001). CONCLUSIONS: The Spanish version of the UCLA-
PCI in general showed acceptable psychometric properties,
though further investigation of the substantial ceiling and ﬂoor
effects are required.
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Erlotinib (TarcevaTM) is an oral highly speciﬁc epidermal growth
factor receptor tyrosine kinase inhibitor. Phase II/III clinical trials
have shown clinical efﬁcacy of erlotinib in advanced (stage III/IV)
Non-Small-Cell Lung Cancer (NSCLC) in terms of survival and
increased Health Related Quality-of-Life (HRQoL). There is
limited information of HRQoL and resources utilization on
Canadian population of NSCLC. OBJECTIVE: To determine the
HRQoL and resource utilization components in Canadian
patients with stage III/IV NSCLC. METHODS: A face-to-face
survey was conducted on a cohort of 32 patients with stage III/IV
NSCLC from the lung cancer clinic at Princess Margaret Hospi-
tal, Toronto. HRQoL was assessed using disease speciﬁc tools
(FACT-L). Utility scores were assessed by EQ-5D US English
version. Socio-economic, clinical, and resource utilization data
were collected using a self-administered questionnaire. Partici-
pants’ clinic charts were reviewed for supportive data and veri-
ﬁcation. RESULTS: Mean age was 63.03 ± 10.39 years, 23 were
females and 68.8% have been smokers. Mean time since cancer
diagnosis was 24.06 ± 17.74 months, 78.1% had metastasis. The
average FACT-L score was 99.64 (range: 90–130), the FACT-
L/TOI score was 57.43. The average EQ-5D score was 0.533,
the score for Current Health State was 59.38 (0–10 scale). Mean
number of visits to oncology clinic was 1.06 ± 0.74/month, and
0.86 ± 0.84/month for family physicians. Patients have been hos-
pitalized for 4.13 ± 4.26 days on average in previous year. The
average cost of medical imaging was CAD403.21 ± CAD81.27,
mean cost of lab test was CAD44.72 ± CAD9.02, and mean 
cost of non-chemotherapy drugs was CAD44.51 ± CAD65.25.
Average cost of Chemotherapy drugs was CAD460.70 ±
CAD98.70. CONCLUSION: Advanced NSCLC patients on
chemotherapy use substantial health care resources in Canadian
setting. However, if not in end stage of life, patients have high
HRQoL and utility scores that warrant further investigation.
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OBJECTIVES: The aim of this study was to develop health state
descriptions for patients receiving chemotherapy for stable,
responding and progressive metastatic breast cancer (MBC).
Subsequent work will derive utility values for the health states
for use in cost utility analyses. METHODS: An interview dis-
cussion guide was produced based on literature review and clin-
ical input. This focused on the symptoms of MBC, impact on
different areas of functioning (physical, social, emotional, sexual,
and cognitive), health related quality of life (HRQL), severe hair
loss and ﬁve side effects of chemotherapy (all grade III–IV toxi-
cities). These included febrile neutropenia, hand-foot syndrome,
diarrhoea/vomiting, stomatitis, and fatigue. Health states were
developed and validated using cognitive debrieﬁng interviews
with oncologists and a focus group with oncology specialist
nurses. Fifteen health states (7 stable, 7 responding, 1 progres-
sive) described the symptoms, toxicities, HRQL and impact on
functioning. Health states combined stable, responding and pro-
gressive disease with grade III–IV side effects or hair loss. To sim-
plify the preference elicitation stage of this study the number of
health states were reduced by employing an orthogonal frac-
tional factorial design to combine disease stages with toxicities.
The contributory effect of each will be estimated using a regres-
sion model. RESULTS: Four main areas of functioning, physi-
cal, emotional, social and sexual, were identiﬁed as being
primarily affected in MBC. Patients responding to treatment
have the highest overall HRQL while those with progressive
disease have the lowest. The focus group discussion supported
the validity of the health states. CONCLUSION: Health states
describing the combined impact of MBC and grade III–IV toxi-
cities associated with chemotherapy treatment on patient’s
HRQL at different disease stages were developed. These health
states will be piloted and used in a societal based valuation study.
The ﬁnal health states will be presented.
PCN50
A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT
OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-
SMALL-CELL LUNG CANCER PATIENTS RECEIVING SECOND-
LINE CHEMOTHERAPY
Tilden D1, Hill G1,Watt M2, Bhalla S3
1M-TAG, A division of IMS Health Economics and Outcomes
Research, London, UK; 2Eli Lilly and Company, Basingstoke, UK; 3Eli
Lilly and Company, Surrey, UK
OBJECTIVES: In clinical trials, chemotherapy-related adverse
events (AEs) are classiﬁed according to the Common Toxicity
Criteria (CTC). This standardised method of reporting provides
clinicians with an overview of the level of medical intervention
required to treat AEs, but does not necessarily assess the impact
on a patient’s health-related quality of life (HRQL). We attempt
to translate CTC (version 2.0) ratings into a scale that reﬂects
the severity of various events on a patient’s HRQL. METHODS:
In this study, scores of impact on patient HRQL were assigned
to AEs experienced by advanced non-small cell lung cancer
(NSCLC) patients receiving second-line chemotherapy. This was
achieved through a pilot survey of a convenience sample of
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twelve physicians. A mapping instrument was developed to allo-
cate values of HRQL impact to ﬁfty chemotherapy-related AEs.
The HRQL impact was measured on a ﬁve-point scale for direct
comparison with the CTC. RESULTS: This analysis revealed that
approximately half (23 of 50) of the AEs had HRQL impact
values that were different to their CTC grades. For the majority
(17 of 23), the HRQL impact value was lower than the CTC
grade. The results of the HRQL impact survey conﬁrmed that
the CTC classiﬁcation does not always reﬂect the impact on
patient HRQL and that in general, low to moderate grade
leukopenic and thrombocytopenic haematological events have
lower impact on patient HRQL than non-haematological events.
Vomiting, pain, sensory neuropathy, rigors, chills and fever had
a higher impact on HRQL than the CTC would suggest. CON-
CLUSIONS: We have proposed a method for estimation of the
HRQL impact of AEs on chemotherapy patients that has face
validity. This research provides a basis to quantify the HRQL
impact of chemotherapy-related AEs. This could then be used to
assess the value of various chemotherapy agents in cost-utility
analyses.
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OBJECTIVE: To develop a short new scale to assess patient per-
ceptions of cancer-related fatigue (CRF), and determine the
beliefs and expectations of cancer patients with CRF.
METHODS: To deﬁne the ﬁrst version of the questionnaire a
two-phase methodology was used. Firstly, initial item content
was deﬁned by integrating information from: 1) a literature
review performed to identify related studies; 2) content analysis
of two focus groups carried out with cancer patients; and 3) two
expert meetings with oncologists. To reduce the item pool and
produce the ﬁrst version of the questionnaire for validation, a
multicentre cross-sectional study was performed and the item
pool was administered to a sample of the target population. Item
reduction was based on a clinimetric approach, so that for each
item in the initial pool, frequency and importance were assessed
by a Likert scale and the frequency and importance product
index (PI) was calculated. Item selection was based on the order-
ing of items based on the PI. RESULTS: The initial item pool
included 75 double-items referring to mental attitude (7), social
and family (15), psychological impact (12), physical functioning
(12), daily life activities (12) and general opinions (17). Initial
pool was administered to 238 cancer patients: mean age 57, 56%
women, 30% breast cancer, 46% with anemia, average of low-
to-moderate CRF intensity. 95% of sample responded at least
85% of items. Average of missing items per patient was 4.5. PI
ranged from 4.9 to 12.4 and the ﬁrst 40 items were selected and
preliminarily assigned to six dimensions (physical, social, psy-
chological, attitudes, daily life activities, opinions). CONCLU-
SION: Preliminary results from the item reduction process have
led to a ﬁrst version of the questionnaire with 40 items and six
dimensions. The next stage will examine the psychometric prop-
erties of the new measure in a larger sample.
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OBJECTIVES: To establish whether a standard questionnaire
exists for evaluating quality of life (QoL) in patients with mCRC.
METHODS: We conducted a search of the published literature
on QoL, chemotherapy, and colorectal cancer between 1998 and
2004, excluding studies with limited total sample sizes (<50). We
reviewed twenty studies with unique patient populations cover-
ing nine QoL questionnaires and nine chemotherapy drugs.
RESULTS: Most studies were conducted in Europe (primarily the
UK), average sample size was 184 patients per study arm (range:
25, 411). The EORTC QLQ-C30 was the most commonly used
questionnaire (17 studies). Generally, it was administered in
treatment trials starting at baseline and every 6 weeks thereafter
until disease progression (on average 2 years duration). Few
EORTC QLQ-C30 studies (2 of 15 multi-arm studies) were able
to detect differences between groups other than on the diarrhea
item. Recently, two supplemental CRC speciﬁc modules were
developed, the EORTC QLQ-CR38 and FACT-C. While the
EORTC QLQ-CR38 module focuses more on symptoms, the
FACT-C considers patients’ attitudes towards their cancer. One
study used the EORTC QLQ-CR38 and was able to detect treat-
ment group differences in symptoms; speciﬁcally, stoma-related,
micturition, defecation, and sexual problems, gastrointestinal
tract symptoms, body image, and future perspective. Another
study used the FACT-C along with other FACT speciﬁc modules
to compare QoL across different cancer types. Minimal differ-
ences (due to the small sample size in each cancer type) were
observed. CONCLUSIONS: The EORTC QLQ-C30 is the most
commonly used questionnaire in mCRC patients receiving
chemotherapy. With increased use and availability of transla-
tions, the EORTC QLQ-CR38 and FACT-C will likely prove to
be more sensitive in detecting differences. Common patterns
exist for the administration (coinciding with cycles) and dura-
tion of follow-up (≥1 year), yet no standard QoL questionnaire
emerged able to detect group differences for mCRC patients
receiving chemotherapy.
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OBJECTIVE: Patient Satisfaction and Quality in Oncological
Care (PASQOC®) 2002 was the ﬁrst assessment in Germany
focusing on patient satisfaction in oncology. In 2004 PASQOC®
was rerun to assess and observe quality of oncological care over
time (2002/2004). Of 49 participating practices and ambulances,
16 were following-up on their 2002 experience. METHODS: All
cancer patients presenting at the investigators’ practices within
a deﬁned recruiting period received the validated questionnaire
PASQOC® via mail. Patients’ inclusion criteria: German speak-
ing, ≥18 years, conﬁrmed cancer diagnosis, physical/mental
ability to complete self-administered questionnaire. Analysis
based on dichotomous “problem scores” indicating the presence
or absence of a problem. These are summed into 13 “dimension
